



## COMUNICATO STAMPA

### UPDATE OF THE CORPORATE EVENTS CALENDAR 2015

Capua, 19 April 2015 – Also pursuant to Article 2.6.2 of Borsa Italiana S.p.A., Pierrel S.p.A. (“**Pierrel**” or the “**Company**”) discloses that the meeting of the Shareholders to consider and approve of the financial statement of the Company at 31 December 2014 and for the renewal of the corporate bodies will not be held in the week of 19 to 26 May 2015, as previously announced to the market on the 23 January past, but will be held on the 5 June 2015.

\*\*\*

**Pierrel S.p.A.**, is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma division).

The Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“DRR2.0”) and Integrated Clinical Development Services (“ICDS”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 23 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical use. The database can be accessed by molecule or by illness.

Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

#### For further information:

##### **Pierrel S.p.A.**

Investor Relations

Raffaele Petrone

e-mail: [investor.relations@pierrelgroup.com](mailto:investor.relations@pierrelgroup.com)

tel. +39 02 36695100

fax +39 02 36695129

##### **Global Consult S.r.l.**

Media Relations

Rossana Del Forno

e-mail: [areacomunicazione@globalconsultsrl.com](mailto:areacomunicazione@globalconsultsrl.com)

tel. +39 333 6178665